#160591

MHYO-LCL1 Pre-leukaemic (DNMT3a R882H mutant) Human B-lymphoblast Cell Line

Cat. #160591

MHYO-LCL1 Pre-leukaemic (DNMT3a R882H mutant) Human B-lymphoblast Cell Line

Cat. #: 160591

Sub-type: Primary

Unit size: 1x10^6 cells / vial

Organism: Human

Tissue: Blood

Disease: Cancer

Model: Tumour line

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: MIchal Hayun

Institute: Rambam Health Care Campus

Tool Details
Target Details
Applications
Handling
Related Tools

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: MHYO-LCL1 Pre-leukaemic (DNMT3a R882H mutant) Human B-lymphoblast Cell Line
  • Cancer: Blood cancer
  • Cancers detailed: Leukaemia;Pre-leukaemia
  • Research fields: Cancer
  • Tool sub type: Primary
  • Parental cell: Novel patient-derived (male; acute myeloid leukaemia) cell line
  • Organism: Human
  • Tissue: Blood
  • Disease: Cancer
  • Growth properties: Confirmed antigen expression: CD19, CD20, CD27, CD45, HLA-DR, CD49d. Cytokine secretion: IL-10
  • Model: Tumour line
  • Conditional: No
  • Description: THe MYHO-LCL cell line is very unique since it carries the pre-leukaemia DNMT3a R882H mutation, and therefore is useful in the investigation of B lymphocyte lineages. The cell line phenotype is of memory B lymphocytes, and therefore is relevant to B-cell development, oncology, and immunology. Relevant research areas include: Drug discovery, B-cell biology, B-cell development and transformation, aging, and acute myeloid leukaemia.These cells are monoclonal as confirmed by IGH gene clonality assay.
  • Production details: This cell line was spontaneously grown from peripheral blood drawn from a male acute myeloid leukaemia patient upon diagnosis. This line was established in culture four weeks after seeding the AML blast cells. The cells contain low EBV mRNA expression and secret EBV into media, confirming immortalisation and transformation. These cells are in suspension and mostly grow as aggregates.

Target Details

  • Target: DNMT3a R882H mutant

Applications

  • Application notes: Relevant research areas include: Drug discovery, B-cell biology, B-cell development and transformation, aging, and acute myeloid leukaemia. These cells are monoclonal as confirmed by IGH gene clonality assay.

Handling

  • Format: Frozen
  • Growth medium: Cells have been grown in IScove Modified Dulbecco's Medium containing 10% foetal bovine serum and 1% pencicillin/streptomycin. Cells are grown at 37 degrees celsius and 5% CO2. Cultures were split at confluency 1:2 or 1:3 two or three times per week.
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice

Related Tools

  • Related tools: MHYO-LCL2 Human B-lymphoblast Cancer Cell Line